iShares MSCI World ETF: A Golden Cross Meets Record Bank Profits

A golden cross technical signal and record earnings from financial & tech holdings propel the iShares MSCI World ETF, though new tariffs and fee competition pose risks.

A potent technical signal flashed for the iShares MSCI World ETF in mid-April as its 10-day moving average crossed decisively above the 50-day average. Chart analysts view this ‘golden cross’ as a robust buy indicator, historically followed by further price gains in the subsequent month 85% of the time. This bullish pattern coincides with a record-breaking earnings season from its heavyweight financial holdings, creating a powerful dual narrative for the fund.

The fund’s recent strength is fundamentally anchored by the US technology sector, which commands a dominant portfolio weight of nearly 27%. Nvidia, Apple, and Microsoft alone account for over 13% of the ETF’s roughly $7.9 billion in assets under management. Analysts attribute the sector's performance to resilient profit margins, particularly within the artificial intelligence space, supported by a sturdy US economy.

Simultaneously, the financial sector—the fund's second-largest allocation at over 16%—is delivering historic results. Three US banking giants reported record first-quarter 2026 figures. JPMorgan posted trading revenue of $11.6 billion, a yearly record representing a 20% annual increase, with earnings per share of $5.94 beating analyst estimates by about nine percent. Morgan Stanley’s quarterly revenue surpassed $20 billion for the first time, while its profit jumped 29% to $5.57 billion.

Trading near its 52-week high of $193.60, the ETF has gained nearly 10% in just two weeks. Its price-to-earnings ratio stands at approximately 25. A brief breakout above the upper Bollinger Band in early April raised minor overbought concerns, but a swift stabilization above key support levels quickly reassured the market.

However, the outlook is not without significant headwinds. New US pharmaceutical tariffs, set to take effect at the end of July 2026, pose a direct risk. The staged rates include 15% on imports from the EU, Japan, South Korea, and Switzerland, and 10% for UK manufacturers, with firms lacking US pricing agreements facing potential 100% duties. Given the healthcare sector's 9.5% portfolio weighting, analysts estimate these tariffs could add around 0.5 percentage points to global inflation.

Furthermore, competitive pressure is mounting on the cost front. Invesco cut the management fee for its competing MSCI World ETF to 0.05% in early April, making the iShares fund (URTH) 19 basis points more expensive than its cheapest rival. BlackRock counters this by highlighting the fund’s tracking difference of just 0.02%. Institutional loyalty appears intact for now, evidenced by the Royal Bank of Canada recently increasing its position by 17.5% to approximately two million shares.

Looking ahead, structural changes loom. The upcoming MSCI semi-annual review in May introduces a new free-float classification system, which analysts expect to trigger significantly larger portfolio shifts than the first quarter's rebalance, which saw only 18 additions and 27 deletions. Investors are also anticipating the ex-dividend date on June 15, following a year where the fund's dividend growth exceeded 20%.

While FactSet has trimmed its S&P 500 Q1 earnings growth forecast from 13.4% to 12.5%, even the revised figure would mark a sixth consecutive quarter of double-digit growth—the longest such streak in over a decade. The fund’s trajectory will hinge on this earnings resilience continuing to outweigh the pressures from new tariffs and an intensifying fee war.